The DOI matches its Crossref record.
High glucose‐induced activation of the polyol pathway and changes of gene expression profiles in immortalized adult mouse Schwann cells IMS32
Abstract
We investigated the polyol pathway activity and the gene expression profiles in immortalized adult mouse Schwann cells (IMS32) under normal (5.6 m m) and high (30 and 56 m m) glucose conditions for 7–14 days in culture. Messenger RNA and the protein expression of aldose reductase (AR) and the intracellular sorbitol and fructose contents were up‐regulated in IMS32 under high glucose conditions compared with normal glucose conditions. By employing DNA microarray and subsequent RT–PCR/northern blot analyses, we observed significant up‐regulation of the mRNA expressions for serum amyloid A3 (SAA3), angiopoietin‐like 4 (ANGPTL4) and ecotropic viral integration site 3 (Evi3), and the down‐regulation of aldehyde reductase (AKR1A4) mRNA expression in the cells under high glucose (30 m m) conditions. The application of an AR inhibitor, SNK‐860, to the high glucose medium ameliorated the increased sorbitol and fructose contents and the reduced AKR1A4 mRNA expression, while it had no effect on mRNA expressions for SAA3, ANGPTL4 or Evi3. Considering that the exposure to the high glucose (≥ 30 m m) conditions mimicking hyperglycaemia in vivo accelerated the polyol pathway in IMS32, but not in other previously reported Schwann cells, the culture system of IMS32 under those conditions may provide novel findings about the polyol pathway‐related abnormalities in diabetic neuropathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Previous studies on hyperglycemia and Angptl4 expression used very high levels of glucose, much beyond those that occur in vivo in the CNS, even in diabetes.
“Although it has been suggested that hyperglycemia might regulate Angptl4 expression [33], these previous studies were done with very high levels of glucose, much beyond those that occur in vivo in the CNS, even in diabetes.”
From Differential effects of angiopoietin-like 4 in brain and muscle on regulation of lipoprotein lipase activity (2015) · cites this paper as [33]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 66
- 10.1016/S0925-4773(00)00293-8 · DOI
- 10.1016/S0021-9258(18)60566-6 · DOI
- 10.1016/j.molbrainres.2004.05.002 · DOI
- 10.1007/s001250050921 · DOI
- 10.1093/jnen/63.11.1144 · DOI
- 10.3109/13506120009146246 · DOI
- 10.2174/0929867033457368 · DOI
- 10.1161/hh2101.098613 · DOI
- 10.1097/00005072-199612000-00001 · DOI
- 10.1016/S0074-7742(02)50081-7 · DOI
- 10.1210/en.143.4.1213 · DOI
- 10.1016/0026-0495(86)90197-6 · DOI
- 10.1159/000016291 · DOI
- 10.1021/ac00268a010 · DOI
- 10.1111/j.1432-1033.1995.tb20408.x · DOI
- 10.1258/000456304322880005 · DOI
- 10.1128/MCB.20.16.5840-5846.2000 · DOI
- Huey P. U., 1998, Lipoprotein lipase is expressed in cultured Schwann cells and functions in lipid synthesis and utilization, J. Lipid Res., 39, 2135, 10.1016/S0022-2275(20)32468-8 · DOI
- 10.1016/S0009-2797(02)00193-X · DOI
- Kato K., 2003, Effect of high glucose and C‐peptide on proliferation and MAP kinase activity in cultured immortalized mouse Schwann (IMS32) cells, J. Peripher. Nerv. Syst. (Abstr.), 8, 183
- 10.1016/S0006-2952(99)00121-5 · DOI
- 10.1016/S1566-0702(01)00385-X · DOI
- 10.1016/0167-4838(89)90090-3 · DOI
- 10.1007/BF01011860 · DOI
- 10.1074/jbc.M004029200 · DOI · Paper page
- 10.1002/(SICI)1097-4547(19990715)57:2<280::AID-JNR14>3.0.CO;2-U · DOI
- 10.1016/S0002-9440(10)64285-X · DOI
- 10.1111/j.1432-1033.1995.1059g.x · DOI
- 10.1074/jbc.M107101200 · DOI
- Low P. A., 1999, Diabetic Neuropathy, 317
- 10.1016/S0169-328X(01)00009-2 · DOI
- 10.1002/med.10024 · DOI
- 10.1073/pnas.89.17.7949 · DOI
- Mizisin A. P., 2003, Textbook of Diabetic Neuropathy, 83
- Mizisin A. P., 1996, Polyol pathway and osmoregulation in JS1 Schwann cells grown in hyperglycemic and hyperosmotic conditions, Am. J. Physiol., 270, F90
- 10.1016/S0304-3940(97)00416-3 · DOI
- Nakamura J., 2003, Effect of bFGF on Schwann cell growth and diabetic neuropathy in rats, J. Peripher. Nerv. Syst. (Abstr.), 8, 188
- 10.1016/0925-4439(94)90022-1 · DOI
- 10.1016/S0074-7742(02)50071-4 · DOI
- 10.1007/s10038-005-0278-0 · DOI
- 10.1093/jnen/60.7.686 · DOI
- 10.1006/exnr.2000.7591 · DOI
- 10.1172/JCI4711 · DOI
- 10.1016/S0024-3205(02)02040-4 · DOI
- 10.1046/j.1460-9568.2003.03102.x · DOI
- 10.1016/S0167-4889(00)00087-2 · DOI
- 10.1042/0264-6021:3440007 · DOI
- 10.1002/jnr.10247 · DOI
- 10.1038/sj.bjp.0703328 · DOI
- 10.1016/S1044-7431(03)00096-4 · DOI
- 10.1006/bbrc.1995.2835 · DOI
- 10.2337/diabetes.54.8.2460 · DOI · Paper page
- 10.1093/oxfordjournals.jbchem.a021944 · DOI
- 10.1002/(SICI)1097-4547(19990815)57:4<495::AID-JNR9>3.0.CO;2-Y · DOI
- 10.1111/j.1530-0277.2004.tb03227.x · DOI
- 10.1016/1056-8727(94)00022-G · DOI
- 10.1021/bi00004a038 · DOI
- Tomlinson D. R., 1999, Diabetic Neuropathy, 330
- Vander Jagt D. L., 1992, Reduction of trioses by NADPH‐dependent aldo–keto reductases. Aldose reductase, methylglyoxal, and diabetic complications, J. Biol. Chem., 267, 4364, 10.1016/S0021-9258(18)42844-X · DOI
- 10.1182/blood-2002-08-2652 · DOI
- 10.1002/jnr.490410215 · DOI
- 10.1111/j.1529-8027.2001.01012.x · DOI
- 10.1046/j.1440-1789.2003.00478.x · DOI
- Yabe‐Nishimura C., 1998, Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications, Pharmacol. Rev., 50, 21, 10.1016/S0031-6997(24)01347-4 · DOI
- 10.1016/S0301-0082(03)00034-0 · DOI
- 10.1194/jlr.C200010-JLR200 · DOI · Paper page
Cited by
Sorted by citations
Ooi, A., Wong, J.-C., Petillo, D., Roossien, D., Perrier-Trudova, V., Whitten, D., Min, B. W. H., Tan, M.-H., Zhang, Z., Yang, X. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.024 · Cited by 401
Vienberg, S. G., Kleinridders, A., Suzuki, R., & Kahn, C. R. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.11.003 · Cited by 33
Metadata
- Authors
- Sango, K., Suzuki, T., Yanagisawa, H., Takaku, S., Hirooka, H., Tamura, M., & Watabe, K.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2006-05-12
- Volume
- 98
- Issue
- 2
- Pages
- 446-458
- ISSN
- 0022-3042
- 1471-4159
- Cited by
- 49
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review